BITWISE MARA INCOME STRAT (IMRA) Stock Price & Overview
NYSEARCA:IMRA • US0917487078
The current stock price of IMRA is 12.889 USD. Today IMRA is down by -8.23%. In the past month the price increased by 6.8%.
IMRA Key Statistics
- Market Cap
- 338.129M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- N/A
- Dividend Yield
- N/A
IMRA Stock Performance
IMRA Stock Chart
IMRA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IMRA.
IMRA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 28.33 | 934.238B | ||
| JNJ | JOHNSON & JOHNSON | 20.64 | 579.34B | ||
| MRK | MERCK & CO. INC. | 22.37 | 286.278B | ||
| PFE | PFIZER INC | 9.06 | 153.814B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.52 | 122.779B | ||
| ZTS | ZOETIS INC | 17.16 | 51.259B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.79 | 26.195B | ||
| VTRS | VIATRIS INC | 5.64 | 16.304B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.21 | 11.614B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.303B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.501B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 4.547B | ||
| AMRX | AMNEAL PHARMACEUTICALS INC | 13.57 | 4.166B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find more ETFs on the USA exchanges | Find stocks with similar TA and Setup ratings on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges
BITWISE MARA INCOME STRAT / IMRA FAQ
What does IMRA do?
Imara, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Brookline, Massachusetts and currently employs 6 full-time employees. The company went IPO on 2020-03-12. The firm is focused on developing and commercializing therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases. Its lead product candidate, tovinontrine (IMR-687), is an oral, highly selective, potent small molecule inhibitor of phosphodiesterase-9 (PDE9). PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule. IMR-687 is in Phase IIb clinical development for the treatment of sickle cell disease (SCD) and beta- thalassemia. The company is also focused on initiating a Phase II clinical trial of IMR-687 in heart failure with preserved ejection fraction (HFpEF). The firm is also focused on development of IMR-261, an oral, clinic-ready activator of nuclear factor erythroid 2-related factor 2 (Nrf2).
What is the current price of IMRA stock?
The current stock price of IMRA is 12.889 USD. The price decreased by -8.23% in the last trading session.
How is the ChartMill rating for BITWISE MARA INCOME STRAT?
IMRA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 0 out of 10.